Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode

被引:474
作者
Rossi, S
Buscarini, E
Garbagnati, F
Di Stasi, M
Quaretti, P
Rago, M
Zangrandi, A
Andreola, S
Silverman, D
Buscarini, L
机构
[1] Hosp Piacenza, Dept Gastroenterol, I-29100 Piacenza, Italy
[2] Natl Canc Inst, Dept Radiol, I-20122 Milan, Italy
[3] Hosp Piacenza, Dept Radiol, I-29100 Piacenza, Italy
[4] Hosp Piacenza, Dept Human Pathol, I-29100 Piacenza, Italy
[5] Natl Canc Inst, Dept Human Pathol, I-20133 Milan, Italy
[6] Radiofrequency Interstitial Thermal Ablat Med Sys, Palo Alto, CA 94306 USA
关键词
D O I
10.2214/ajr.170.4.9530052
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
OBJECTIVE, The aim of this study was to evaluate the usefulness of expandable RF needle electrodes in the treatment of hepatic cancer. SUBJECTS AND METHODS, Thirty-seven patients, 23 of whom had 26 hepatocellular carcinoma nodules and 14 of whom had 19 hepatic metastatic nodules, underwent treatment by RF interstitial thermal ablation with expandable needle electrodes. Forty-five tumor nodules were treated in 64 RF interstitial thermal ablation sessions with 83 needle electrode insertions, The mean diameter of the tumor nodules was 2.5 cm (range, 1.1-3.5 cm). Immediate posttreatment tumor necrosis was evaluated by dynamic CT in all cases. Two patients with hepatocellular carcinoma and three patients with metastases underwent surgical resection 20-60 days after RF treatment. The remaining 32 patients were followed up clinically. RESULTS. The mean number of RF interstitial thermal ablation sessions to complete tumor nodule treatment was 1.4, Mean number of needle electrode insertions was 1.8. No complications were observed. Posttreatment dynamic CT showed a completely nonenhancing area in the site of the treated tumor in 44 of 45 cases. The remaining patient with metastatic disease had persistent enhancing tissue. Histology showed complete necrosis in four treated tumor nodules and residual viable cancer in one. Twenty-one patients with hepatocellular carcinoma were followed up for 6-19 months (mean, 10 months). Of these patients, six showed recurrences and 15 remained apparently disease-free. Two patients died, one from advanced cancer and one from other causes. Eleven patients with hepatic metastases were followed up for 7-20 months (mean, 12 months). Of these patients, nine showed recurrent disease and only two remained apparently disease-free. Two patients died from disseminated disease, CONCLUSION. RF interstitial thermal ablation of hepatic tumor by expandable needle electrodes is a safe and effective technique. Local ablation of tumors not exceeding 3.5 cm in diameter is achieved in a short time without complications.
引用
收藏
页码:1015 / 1022
页数:8
相关论文
共 28 条
  • [21] Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer
    Rossi, S
    DiStasi, M
    Buscarini, E
    Quaretti, P
    Garbagnati, F
    Squassante, L
    Paties, CT
    Silverman, DE
    Buscarini, L
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 1996, 167 (03) : 759 - 768
  • [22] Rossi S, 1993, J Interv Radiol, V8, P97
  • [23] SEKI T, 1994, CANCER, V74, P817, DOI 10.1002/1097-0142(19940801)74:3<817::AID-CNCR2820740306>3.0.CO
  • [24] 2-8
  • [25] PERCUTANEOUS ETHANOL INJECTION THERAPY FOR LIVER NEOPLASMS
    SHIINA, S
    NIWA, Y
    OMATA, M
    [J]. SEMINARS IN INTERVENTIONAL RADIOLOGY, 1993, 10 (02) : 57 - 68
  • [26] Percutaneous US-guided radio-frequency tissue ablation of liver metastases: Treatment and follow-up in 16 patients
    Solbiati, L
    Ierace, T
    Goldberg, SN
    Sironi, S
    Livraghi, T
    Fiocca, R
    Servadio, G
    Rizzatto, G
    Mueller, PR
    DelMaschio, A
    Gazelle, GS
    [J]. RADIOLOGY, 1997, 202 (01) : 195 - 203
  • [27] SOLBIATI L, 1996, RADIOLOGY, V201, P268
  • [28] HEPATIC ARTERIAL EMBOLIZATION FOR HEPATOCELLULAR-CARCINOMA - COMPARISON OF CT SCANS AND RESECTED SPECIMENS
    TAKAYASU, K
    MORIYAMA, N
    MURAMATSU, Y
    SUZUKI, M
    YAMADA, T
    KISHI, K
    HASAGAWA, H
    OKAZAKI, N
    [J]. RADIOLOGY, 1984, 150 (03) : 661 - 665